摘要
[目的]观察罗格列酮对急性胰腺炎患者肝损伤的保护作用。[方法]选取2013年2月~2016年1月我院收治的急性胰腺炎患者90例,使用数字法随机分为常规治疗对照组和罗格列酮观察组,每组45例。ELISA法检测ALT、AST、TNF-α和IL-1。比较2组临床疗效。[结果]治疗前对照组和观察组ALT、AST、TNF-α和IL-1表达无显著性差异（P〉0.05）。治疗5d后2组ALT、AST、TNF-α和IL-1表达均减低（P〈0.05和P〈0.01）,但观察组对ALT、AST、TNF-α和IL-1的减低作用均优于对照组（P〈0.05和P〈0.01）。对照组腹痛、腹胀缓解时间、排气、通便时间、体温恢复正常时间以及住院时间分别为：5.17±1.09d、4.95±1.02d、4.56±0.82d和15.27±3.81d,均显著高于观察组的3.44±0.76d、3.26±0.75d、3.13±0.64d和9.86±3.06d（P〈0.05）。观察组的临床治疗有效率为88.9%（40/45）,显著优于对照组的71.1%（32/45）（P〈0.05）。[结论]罗格列酮抑制急性胰腺炎患者炎症反应,保护肝功能,临床疗效显著。
[Objective]To detect the effect of Rosiglitazone on hepatic injury in patients with acute pancreatitis.[Methods]Ninety acute pancreatitis patients were enrolled in this study.Patients were divided into：control group（n=45）and Rosiglitazone observation group（n=45）.ALT,AST,TNF-α,and IL-1expression was detected by ELISA analysis.The clinical effect was compared.[Results]There was no significant difference in the levels of ALT,AST,TNF-α,and IL-1expression between the two groups before treatment（P〈0.05）.Five days after treatment,ALT,AST,TNF-α,and IL-1expression was lower in observation group than that in control group（P〈0.05 and P〈0.01）.Abdominal pain and abdominal distension recovery time,exhaust gas and defecation recovery time,temperature recovery time,and hospitalization time was5.17±1.09 d,4.95±1.02 d,4.56±0.82 d,and 15.27±3.81 din control group,which was significantly higher than that of 3.44±0.76 d,3.26±0.75 d,3.13±0.64 d,and 9.86±3.06 din observation group（P〈0.05 and P〈0.01）.The clinical effect rate in observation was 88.9%（40/45）,which was higher than that of 71.1%（32/45）in control group（P〈0.05）.[Conclusion]Rosiglitazone inhibits the inflammatory reaction to protect the hepatic injury in patients with acute pancreatitis,with significantly clinical effect.
出处
《中国中西医结合消化杂志》
CAS
2016年第11期877-879,共3页
Chinese Journal of Integrated Traditional and Western Medicine on Digestion
关键词
罗格列酮
急性胰腺炎
肝损伤
Rosiglitazone
acute pancreatitis
hepatic injury
